Chiesi Farmaceutici SpA, the Italian healthcare group, has enlisted the expertise of US-based Moderna Inc in order to discover and develop new therapeutics for the treatment of pulmonary arterial hypertension (PAH), a progressive disorder characterised by high blood pressure in the arteries of the lungs. The companies will use Moderna’s messenger RNA (mRNA) technology as the basis for their research.
